- Conditions
- ADHD
- Interventions
- KP415 oral capsule
- Drug
- Lead sponsor
- Zevra Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Bradenton, Florida + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
- Interventions
- methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Problem Behavior
- Interventions
- Stimulant
- Drug
- Lead sponsor
- Matthew J O'Brien, PhD, BCBA-D
- Other
- Eligibility
- 48 Months to 12 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate/dexmethylphenidate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Drug Binding to DAT Receptors
- Interventions
- dex-methylphenidate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Drug
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Northbrook, Illinois
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
- Interventions
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
- Conditions
- ADHD, Autism Spectrum Disorder
- Interventions
- Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
- Drug
- Lead sponsor
- Daniel Coury
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Irvine, California • Los Angeles, California • Portland, Maine + 7 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
- Interventions
- ADHD Medication, Omega-3 Fatty Acids
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Dexmethylphenidate Hydrochloride
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- ADHD
- Interventions
- Focalin XR
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- ADHD
- Interventions
- KP415 oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Zevra Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Guanfacine (GUA), Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Sarcoidosis
- Interventions
- d-methylphenidate
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- ADHD, ADD
- Interventions
- Dexmethylphenidate HCl extended-release capsules
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 252 participants
- Timeline
- 2006
- U.S. locations
- 25
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
- Conditions
- Healthy
- Interventions
- Dexmethylphenidate Hydrochloride
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Guanfacine, Methylphenidate (MPH)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 7 Years to 14 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fatigue, Neoplasms
- Interventions
- dexmethylphenidate(d-mph)
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Tucson, Arizona + 17 more